Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure

Badorrek, Philipp; Müller, Meike; Koch, Wolfgang; Hohlfeld, Jens M.; Krug, Norbert

doi:10.1016/j.anai.2017.01.018

Cited by 37 publications

(37 citation statements)

References 21 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On each exposure visit, one half of the subjects were challenged without any treatment, while the other half received NP. The concentration of grass pollen in the ACC was monitored continuously and kept stable for the duration of the challenges [19].…”

Section: Methodsmentioning

confidence: 99%

“…It was previously used in preclinical experiments as a cytotoxic marker from bronchoalveolar lavage fluid, enabling detection of the inflammatory response in the lungs of rats after exposure to particulate matter, and was, therefore, included in this study. The biomarkers were evaluated from nasal filter eluates pre and post allergen challenge [21]. The cytokines eotaxin, interleukin-3 (IL-3), IL-4, IL-5, IL-6, macrophage inflammatory protein-1β, and tumor necrosis factor α were analyzed in the samples collected pre, 2 h post, and 18 h post challenge, using multiplex assays by Meso Scale Discoveries (Rockville, MD, USA).…”

Section: Biomarker and Cell Analysismentioning

confidence: 99%

“…The aim of the present study was to assess the effect of a single-dose treatment with NP on nasal symptoms in patients with seasonal AR (SAR) under well-defined conditions in an allergen challenge chamber (ACC). This chamber provides a controlled environment for mechanistic and proof-of-concept studies in earlyphase clinical trials, where antiallergic treatments can be tested with fewer subjects compared to field studies [11][12][13][14][15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Effect of a Thixotropic Nasal Gel on Nasal Symptoms and Inflammatory Biomarkers in Seasonal Allergic Rhinitis

Struß¹,

Badorrek²,

Mattern³

et al. 2020

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Background: Drug-free viscous nasal applications have been shown to reduce nasal symptoms in individuals with seasonal allergic rhinitis (SAR). Nascum ® -Plus (NP), a commercially available thixotropic gel, has been designed to reduce dryness and soreness of the nasal mucosa and prevent the absorption of small particles. Objectives: The aim of this study was to assess the efficacy of single-dose NP in treating nasal symptoms and secretion during challenge in an allergen challenge chamber (ACC). Furthermore, the effect of this treatment on biomarkers and immune cells of the allergic cascade were measured. Methods: This open-label, crossover, sequence-randomized, monocentric trial randomized 18 adults with SAR and a positive skin prick test reaction to Dactylis glomerata pollen to receive NP or no treatment during two 4-h ACC sessions 3 weeks apart. On Day 1, 9 subjects were challenged for 4 h with treatment, the other 9 without treatment, and vice versa on Day 22. Nasal lavage fluid and nasal filter eluate samples were obtained pre, 2, and 18 h post challenge in the ACC. Results: NP significantly reduced nasal symptoms, assessed by total nasal symptom score (p < 0.001), and minimized nasal secretion (p = 0.047), while no significant effect on biomarkers and immune cells in the nasal fluid was observed. The treatment was safe and well-tolerated. Conclusions: The physical barrier built by NP nasal gel can be safely applied in patients with allergic rhinitis. It reduces allergic nasal symptoms and secretion, but application of a single dose does not affect local inflammatory biomarkers.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Biomarker and Cell Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of a Thixotropic Nasal Gel on Nasal Symptoms and Inflammatory Biomarkers in Seasonal Allergic Rhinitis

Struß¹,

Badorrek²,

Mattern³

et al. 2020

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our group has published 2 case series describing a rush subcutaneous immunotherapy (SCIT) schedule administered using a subcutaneous infusion pump [1,2], in which the maintenance dose was reached after 3 visits. This type of rush protocol with SCIT provides a rapid clinical response, improved adherence, and increased cost-effectiveness owing to the lower number of visits and doses [3][4][5].…”

Section: Safety Of An Ultrarush (4 Hours) Subcutaneous Immunotherapy mentioning

confidence: 99%

“…Nasal cytology is a convenient method that is very useful in clinical practice, mainly in the diagnostic and prognostic work-up of patients with rhinitis [2]. In addition, it has been reported that the nasal eosinophil count correlates better with symptom severity and IgE level [3,4].…”

mentioning

confidence: 99%

Peripheral Eosinophil Counts Correlate With Nasal Eosinophil Counts in Patients With Rhinitis

Ciprandi¹,

Varricchio

Tajana

et al. 2018

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

Self Cite

113

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure

Abstract: clinicaltrials.gov Identifier: NCT00297843.

Cited by 37 publications

References 21 publications

The Effect of a Thixotropic Nasal Gel on Nasal Symptoms and Inflammatory Biomarkers in Seasonal Allergic Rhinitis

The Effect of a Thixotropic Nasal Gel on Nasal Symptoms and Inflammatory Biomarkers in Seasonal Allergic Rhinitis

Peripheral Eosinophil Counts Correlate With Nasal Eosinophil Counts in Patients With Rhinitis

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Contact Info

Product

Resources

About